Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-04-2020 | Neuroendocrine Tumor | Original Article

Biodistribution and first clinical results of ¹⁸F-SiFAlin-TATE PET: a novel ¹⁸F-labeled somatostatin analog for imaging of neuroendocrine tumors

Authors: Harun Ilhan, S. Lindner, A. Todica, C. C. Cyran, R. Tiling, C. J. Auernhammer, C. Spitzweg, S. Boeck, M. Unterrainer, F. J. Gildehaus, G. Böning, K. Jurkschat, C. Wängler, B. Wängler, R. Schirrmacher, P. Bartenstein

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2020

Abstract

Introduction

PET/CT using ⁶⁸Ga-labeled somatostatin analogs (SSA) targeting somatostatin receptors (SSR) on the cell surface of well-differentiated neuroendocrine tumors (NET) represents the clinical reference standard for imaging. However, economic and logistic challenges of the ⁶⁸Ge/⁶⁸Ga generator-based approach have disadvantages over ¹⁸F-labeled compounds. Here, we present the first in-human data of ¹⁸F-SiFAlin-TATE, a novel ¹⁸F-labeled, SSR-targeting peptide. The aim was to compare the intra-individual biodistribution, tumor uptake, and image quality of ¹⁸F-SiFAlin-TATE to the clinical reference standard ⁶⁸Ga-DOTA-TOC.

Methods

Thirteen patients with NET staged with both ⁶⁸Ga-DOTA-TOC and ¹⁸F-SiFAlin-TATE PET/CT have been included in this retrospective analysis. We compared the biodistribution in normal organs and tumor uptake of NET lesions by SUVmean and SUVmax measurement for tracers. Additionally mean and max tumor-to-liver (TLR) and tumor-to-spleen ratios (TSR) have been calculated by division of SUVmean and SUVmax of tumor lesions by the SUVmean of the liver and spleen, respectively. Additionally, image quality was visually rated by 5 blinded readers and an intra-class correlation (ICC) analysis on inter-observer agreement has been performed.

Results

Compared with ⁶⁸Ga-DOTA-TOC, the biodistribution of ¹⁸F-SiFAlin-TATE showed somewhat higher, however, statistically not significant higher uptake in the liver, spleen, and adrenal glands. Significantly higher uptake was observed in the kidneys. Tumor uptake was higher in most tumor lesions with significantly higher uptake in common metastatic sites of NET including the liver (SUVmax 18.8 ± 8.4 vs. 12.8 ± 5.6; p < 0.001), lymph nodes (SUVmax 23.8 ± 20.7 vs. 17.4 ± 16.1; p < 0.001) and bone (SUVmax 16.0 ± 10.1 vs. 10.3 ± 5.7; p < 0.01) for ¹⁸F-SiFAlin-TATE. The high tumor uptake resulted in favorable TLR and TSR, comparable with that of ⁶⁸Ga-DOTA-TOC. The ICC analysis on the inter-observer agreement on image quality was substantial and almost perfect. Image quality was rated as excellent in most cases in both ⁶⁸Ga-DOTA-TOC and ¹⁸F-SiFAlin-TATE PET.

Conclusion

The favorable characteristics of ¹⁸F-SiFAlin-TATE with a high image quality, the kit-like labeling procedure, and the promising clinical performance enable improved logistics and diagnostic possibilities for PET imaging of NET. Our first clinical results warrant further systematic studies investigating the clinical use of ¹⁸F-SiFAlin-TATE in NET patients.

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42. https://doi.org/10.1001/jamaoncol.2017.0589.CrossRefPubMedPubMedCentral

Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781–93. https://doi.org/10.1007/s00259-003-1184-3.CrossRefPubMed

Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588–601. https://doi.org/10.1007/s00259-017-3728-y.CrossRefPubMed

Banerjee SR, Pomper MG. Clinical applications of Gallium-68. Appl Radiat Isot. 2013;76:2–13. https://doi.org/10.1016/j.apradiso.2013.01.039.CrossRefPubMed

Lottes G, Gorschluter P, Kuwert T, Adam D, Schober O. Costs of F-18-FDG PET: experience with a satellite concept. Nuklearmedizin. 1998;37:159–64 discussion 65.CrossRef

Niedermoser S, Chin J, Wangler C, Kostikov A, Bernard-Gauthier V, Vogler N, et al. In vivo evaluation of (1)(8)F-SiFAlin-modified TATE: a potential challenge for (6)(8)Ga-DOTATATE, the clinical gold standard for somatostatin receptor imaging with PET. J Nucl Med. 2015;56:1100–5. https://doi.org/10.2967/jnumed.114.149583.CrossRefPubMed

Wangler C, Waser B, Alke A, Iovkova L, Buchholz HG, Niedermoser S, et al. One-step (1)(8)F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET). Bioconjug Chem. 2010;21:2289–96. https://doi.org/10.1021/bc100316c.CrossRefPubMed

Schirrmacher R, Bradtmoller G, Schirrmacher E, Thews O, Tillmanns J, Siessmeier T, et al. 18F-labeling of peptides by means of an organosilicon-based fluoride acceptor. Angew Chem Int Ed Engl. 2006;45:6047–50. https://doi.org/10.1002/anie.200600795.CrossRefPubMed

General Assembly of the World Medical A. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014;81:14–8.

10.

Revy A, Hallouard F, Joyeux-Klamber S, Skanjeti A, Rioufol C, Fraysse M. Feasibility and evaluation of automated methods for radiolabeling of radiopharmaceutical kits with gallium-68. Curr Radiopharm. 2019. https://doi.org/10.2174/1874471012666190110170623.CrossRef

11.

Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. (111)in-pentetreotide scintigraphy vs. (68)Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden. J Nucl Med. 2019. https://doi.org/10.2967/jnumed.118.223016.CrossRef

12.

Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.CrossRef

13.

Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology. 2017;105:212–44. https://doi.org/10.1159/000471879.CrossRefPubMed

14.

Waldmann CM, Stuparu AD, van Dam RM, Slavik R. The search for an alternative to [(68)Ga]Ga-DOTA-TATE in neuroendocrine tumor theranostics: current state of (18)F-labeled somatostatin analog development. Theranostics. 2019;9:1336–47. https://doi.org/10.7150/thno.31806.CrossRefPubMedPubMedCentral

15.

Wessmann SH, Henriksen G, Wester HJ. Cryptate mediated nucleophilic 18F-fluorination without azeotropic drying. Nuklearmedizin. 2012;51:1–8. https://doi.org/10.3413/Nukmed-0425-11-08.CrossRefPubMed

16.

Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:514–23. https://doi.org/10.1007/s00259-012-2309-3.CrossRefPubMed

17.

Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, et al. Prognostic value of somatostatin receptor expressing tumor volume calculated from (68)Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04455-9.CrossRef

18.

Fendler WP, Barrio M, Spick C, Allen-Auerbach M, Ambrosini V, Benz M, et al. 68Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessment: results of a prospective study on 50 patients. J Nucl Med. 2017;58:307–11. https://doi.org/10.2967/jnumed.116.179192.CrossRefPubMedPubMedCentral

19.

Sanchez-Crespo A. Comparison of gallium-68 and fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55–62. https://doi.org/10.1016/j.apradiso.2012.06.034.CrossRefPubMed

20.

Aalbersberg EA, de Wit-van der Veen BJ, MWJ V, Saveur LJ, Valk GD, Tesselaar MET, et al. Influence of lanreotide on uptake of (68)Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation. Eur J Nucl Med Mol Imaging. 2019;46:696–703. https://doi.org/10.1007/s00259-018-4117-x.CrossRefPubMed

21.

Galne A, Almquist H, Almquist M, Hindorf C, Ohlsson T, Nordenstrom E, et al. A prospective observational study to evaluate the effects of long-acting somatostatin analogs on (68)Ga-DOTATATE uptake in patients with neuroendocrine tumors. J Nucl Med. 2019. https://doi.org/10.2967/jnumed.119.226332.CrossRef

22.

Krebs S, Pandit-Taskar N, Reidy D, Beattie BJ, Lyashchenko SK, Lewis JS, et al. Biodistribution and radiation dose estimates for (68)Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46:677–85. https://doi.org/10.1007/s00259-018-4193-y.CrossRefPubMed

23.

Guedj E, Graillon T, Chinot O, Taieb D. Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2019;46:537–8. https://doi.org/10.1007/s00259-018-4221-y.CrossRefPubMed

24.

Roll W, Riemann B, Schafers M, Stegger L, Vrachimis A. 177Lu-DOTATATE therapy in radioiodine-refractory differentiated thyroid cancer: a single center experience. Clin Nucl Med. 2018;43:e346–e51. https://doi.org/10.1097/RLU.0000000000002219.CrossRefPubMed

25.

Lapa C, Kircher M, Hanscheid H, Schirbel A, Grigoleit GU, Klinker E, et al. Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients. Theranostics. 2018;8:644–9. https://doi.org/10.7150/thno.22161.CrossRefPubMedPubMedCentral

Title: Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors
Authors: Harun Ilhan
S. Lindner
A. Todica
C. C. Cyran
R. Tiling
C. J. Auernhammer
C. Spitzweg
S. Boeck
M. Unterrainer
F. J. Gildehaus
G. Böning
K. Jurkschat
C. Wängler
B. Wängler
R. Schirrmacher
P. Bartenstein
Publication date: 01-04-2020
Publisher: Springer Berlin Heidelberg
Keyword: Neuroendocrine Tumor
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04501-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Biodistribution and first clinical results of ¹⁸F-SiFAlin-TATE PET: a novel ¹⁸F-labeled somatostatin analog for imaging of neuroendocrine tumors

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2020

Availability of both [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors?

PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest

The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure

Quantifying the effects of absorbed dose from radioembolisation on healthy liver function with [99mTc]TcMebrofenin

Preclinical evaluation of [18F]FB-A20FMDV2 as a selective marker for measuring αVβ6 integrin occupancy using positron emission tomography in rodent lung

Correction to: A multiparametric analysis based on DCE-MRI to improve the accuracy of parotid tumor discrimination